Urine complement proteins are associated with kidney disease progression of type 2 diabetes in Korean and American cohorts - Yun, Donghwan; Bae, Sohyun; Gao, Yuqian; Lopez, Lauren; Han, Dohyun; Nicora, Carrie D.; Kim, Tae Youn; Moon, Kyung Chul; Kim, Dong Ki; Fillmore, Thomas L.; Kim, Yon Su; Rosenberg, Avi Z.; et al. (medRxiv, 2024)
Background Mechanisms of progression of diabetic kidney disease (DKD) are not completely understood. This study uses untargeted and targeted mass spectrometry-based proteomics in two independent cohorts on two continents to decipher the mechanisms of DKD in patients with type 2 diabetes.Methods We conducted untargeted mass spectrometry on urine samples collected at the time of kidney biopsy from Korean patients with type 2 diabetes and biopsy-proven diabetic nephropathy at Seoul National University Hospital (SNUH-DN cohort; n = 64). These findings were validated using targeted mass spectrometry in urine samples from a Chronic Renal Insufficiency Cohort subgroup with type 2 diabetes and DKD (CRIC-T2D; n = 282). Urinary biomarkers/pathways associated with kidney disease progression (doubling of serum creatinine, >=50% decrease in estimated glomerular filtration rates, or the development of end-stage kidney disease) were identified.Results SNUH-DN patients had an estimated glomerular filtration rate (eGFR) of 55 mL/min/1.73 m2 (interquartile range [IQR], 44–75) and random urine protein-to-creatinine ratio of 3.1 g/g (IQR, 1.7–7.0). Urine proteins clustered into two groups, with cluster 2 having a 4.6-fold greater hazard (95% confidence interval [CI], 1.9–11.5) of disease progression than cluster 1 in multivariable-adjusted, time-to-event analyses. Proteins in cluster 2 mapped to 10 pathways, four of the top five of which were complement or complement-related. A high complement score, constructed from urine complement protein abundance, was strongly correlated to 4 of 5 histopathologic DN features and was associated with a 2.4-fold greater hazard (95% CI, 1.0–5.4) of disease progression than a low complement score. Targeted mass spectrometry of the CRIC-T2D participants, who had an eGFR of 42 mL/min/1.73 m2 (IQR, 37–49) and 24-hr urine protein of 0.48 g (IQR, 0.10–1.87), showed that the complement score similarly segregated them into rapid and slow DKD progression groups. In both cohorts, the complement score had a linear association with disease progression.Conclusions Urinary proteomic profiling confirms the association between the complement pathway and rapid DKD progression in two independent cohorts. These results suggest a need to further investigate complement pathway inhibition as a novel treatment for DKD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work is supported by the grant from the SNUH Research Fund (26-2018-0040 to SSH; 26-2022-0040 to SSH), the Richard A. and Nora Eccles Foundation award (A200111 to MA), Richard A. and Nora Eccles Harrison Endowed Chair in Diabetes Research and the Depner Endowed Chair in Nephrology Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For the SNUH-DN cohort, ethical approval was granted by the IRB at SNUH (no. H-2403-066-1519). The use of de-identified samples and data from the CRIC-T2D subgroup from the NIDDK Central Repository was approved by the Human Subjects Division, University of California, Davis.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://www.proteomexchange.org/